September 22, 2023 — Laekna, Inc. (2105.HK), a science-driven, clinical-stage biotechnology company, announced today that the new clinical data of AKT inhibitor Afuresertib (LAE002) in the treatment of breast cancer will be presented in the “Poster Spotlight Discussion” session of the 2023 San Antonio Breast Cancer Symposium (SABCS) on December 8. This is a phase Ib study to evaluate the efficacy and safety of Afuresertib plus Fulvestrant in patients with locally advanced or metastatic HR+/HER2- breast cancer who failed standard of care therapies including CDK4/6 inhibitors.
“We are delighted to share new data of our clinical study of Afuresertib in the ‘Poster Spotlight Discussion’ session of 2023 SABCS,” said Dr. Yong Yue, Chief Medical Officer of Laekna. “We’ve observed positive results among enrolled patients in this study, and we eagerly anticipate that the new drug candidate will soon offer clinical benefits to breast cancer patients.”
The San Antonio Breast Cancer Symposium (SABCS) is an annual event cosponsored by the AACR and UT Health San Antonio’s Mays Cancer Center. This year the meeting hosts about 10,000 clinicians and scientists from all over the world and is the largest and most prestigious scientific gathering on breast cancer research.
Afuresertib (LAE002) is an AKT inhibitor developed by Laekna. According to Frost & Sullivan, it is one of the two AKT inhibitors in the pivotal-stage clinical development for anti-cancer treatment globally. Laekna has initiated multiple clinical studies of combination therapies with Afuresertib in patients with PROC, HR+/HER2− breast cancer, mCRPC, TNBC, PD-1-resistant cervical cancer, and endometrial cancer.
Corporate and Business Development BD@laekna.com
Stock Code: 2105.HK
Founded in 2016, Laekna is a science-driven, clinical-stage biotechnology company committed to bringing novel therapies to cancer and liver fibrosis patients worldwide.
As of June 30, 2023, Laekna has initiated six clinical trials including one pivotal trial for Afuresertib (LAE002), LAE001 and LAE005 to address unmet medical needs in cancers, such as ovarian cancer, breast cancer and prostate cancer. Among the six clinical trials, three are multi-regional clinical trials (MRCTs).
Laekna’s internal drug discovery platform has discovered 12 drug candidates. LAE102 is our first internally discovered antibody which has obtained the IND approval from FDA in May 2023.
Laekna, Inc. was listed on the Main Board of The Stock Exchange of Hong Kong Limited (the “Hong Kong Stock Exchange”) on June 29, 2023, the stock code is 2105.HK.
This press release may contain certain “forward-looking statements” which are not historical facts, but instead are predictions about future events based on Laekna’s current beliefs, assumptions and expectations, commonly identified by words such as "would", "may", "expects", "believes", "plans", "intends", "projects" and other terms with similar meaning. Although we believe that our predictions are reasonable, future events are inherently uncertain and our actual future results or performance may be materially different from what we expect. Accordingly, you are strongly cautioned that reliance on any forward-looking statements is subject to significant known and unknown risks and uncertainties. All forward-looking statements contained herein are qualified by reference to the cautionary statements set forth in this section. All information provided in this press release is as of the date of this press release and are based on assumptions that we believe to be reasonable as of this date, and we do not undertake any obligation to update any forward-looking statement, except as required under applicable law.
Follow us on Linkedin